Merus N.V. (MRUS) ist ein börsennotiertes Unternehmen im Gesundheitswesen Sektor, tätig in der Biotechnologie Branche. Der Hauptsitz des Unternehmens ist in Utrecht, Netherlands. Der aktuelle CEO ist Jan van de Winkel.
MRUS hat IPO-Datum 2016-05-19, 260 Vollzeitbeschäftigte, gelistet an der NASDAQ Global Market, eine Marktkapitalisierung von $6.83B.
Merus N.V. is a clinical-stage immuno-oncology company headquartered in Utrecht, the Netherlands, focused on discovering and developing bispecific antibody therapeutics. The company's pipeline includes several candidates in various development stages, notably Zenocutuzumab (MCLA-128) in Phase 2 trials for metastatic breast cancer, along with MCLA-158, MCLA-145, MCLA-129, and ONO-4685 in Phase 1 or Phase 1/2 trials for various solid tumors and hematologic malignancies. Merus has established strategic collaborations with Betta Pharmaceuticals and Incyte Corporation to advance select candidates in its portfolio. Founded in 2003, the company leverages its bispecific antibody platform to develop novel cancer therapeutics targeting multiple pathways simultaneously.
